Nucleoside Analogs in Cancer Therapy

Nucleoside Analogs: Cellular Pharmacology, Mechanisms of Action, and Strategies for Combination Therapy, William Plunkett and Varsha Gandhi Induction of Apoptosis by Nucleoside Analogs, Peng Huang and Susan Wright Pharmacokinetics of Purine Nucleoside Analogs, Jan Liliemark and Gunnar Juliusson Clinical Development of 2'-Deoxycoformycin, Bruce D. Cheson and Michael R. Grever Clinical Development of Fludarabine, Axel-R. Hanauske and Daniel D. Von Hoff Development of 2-Chlorodeoxyadenosine (2-CdA) as a Chemotherapeutic and Immunosuppressive Drug, Ernest Beutler, Dennis Carson, Robert McMillan, and Robert Longmire Defining the Optimal Dose Schedule of Purine Analogs and Assessment of Response, Jorge E. Cortes and Susan M. O'Brien Clinical Trials of the Purine Analogs in Chronic Lymphocytic Leukemia, Michael J. Keating Treatment of Hairy Cell Leukemia with Nucleoside Analogs, Alan Saven and Lawrence D. Piro Clinical Trials with Nucleoside Analogs in Lymphomas, Wolfgang Hiddemann and Christiane Pott-Hoeck Clinical Trials with Nucleoside Analogs in Other Hematologic Malignancies, Jorge E. Cortes, Hagop Kantarjian, Susan M. O'Brien, and Michael J. Keating Nucleoside Analogs as Radiosensitizing Agents, Vincent Grégoire and Walter N. Hittelman 2-Chlorodeoxyadenosine in Nonmalignant Disorders, Ernest Beutler, Dennis Carson, J. C. Sipe, J. S. Romine, Robert McMillan, Z. M. Younossi, V. D. Rodgers, James A. Koziol, and J. Zyroff Fludarabine in Nonmalignant Disorders, Ioannis O. Tassiulas, John C. Davis, Jr., Barri J. Fessler, Nobuaki Hama, Thomas A. Fleisher, Howard A. Austin III, and Dimitrios T. Boumpas Toxicities Associated with Purine Analog Therapy, Bruce D. Cheson